CVS’s stock soared toward after its quarterly profit beat expectations by the widest margin in more than four years.

SmithRx's 2024 growth comes with continued validation of its transparent, 100% pass-through model, which helps significantly lower costs for employer clients. Paired with Connect 360's innovative ...

CVS appears uniquely positioned to improve health outcomes, and we appreciate management's focus on better leveraging its assets through digital and other means to bring a more consumer-centric ...

The letters were signed by the America’s Agenda, Blue Shield of California, the ERISA Industry Committee, National ...

CVS's stock has gained hiked up 22.5% so far this year, after plunging 43.2% in 2024 to suffer its worst year since 2001. In comparison, the S&P 500 has tacked on 3.2% year to date after rallying 23.3 ...

Sen. Scott Wiener (D-San Francisco) has introduced two bills in the State Senate that could lower prescription drug prices ...

A bill to stop Pharmacy Benefit Managers or PBMs from giving pharmacies less money than it costs to fill prescriptions advanced through the Iowa House Commerce Committee Tuesday.

Ken Paxton's opinion puts Texas on a collision course with employer groups that say ERISA should shield the plans from the ...

Walgreens-Boots Alliance struggles with margin compression, competition, and financial risks. Learn why these challenges make ...

Lawmakers determined to enact new restrictions on pharmacy benefit managers are trying to include legislation, which nearly passed in December, in a budget package that must pass by next month.

Two bills now in the state Senate would clamp down on Pharmacy Benefit Managers, a kind of intermediary between drug companies and local pharmacies.